Parry, Erin M. http://orcid.org/0000-0002-3382-9769
Leshchiner, Ignaty http://orcid.org/0000-0001-8942-9265
Guièze, Romain http://orcid.org/0000-0001-7563-580X
Johnson, Connor
Tausch, Eugen
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Lemvigh, Camilla http://orcid.org/0000-0002-5772-8743
Broséus, Julien http://orcid.org/0000-0002-6689-4006
Hergalant, Sébastien http://orcid.org/0000-0001-8456-7992
Messer, Conor http://orcid.org/0000-0003-4167-7221
Utro, Filippo http://orcid.org/0000-0003-3226-7642
Levovitz, Chaya http://orcid.org/0000-0002-9251-2294
Rhrissorrakrai, Kahn
Li, Liang
Rosebrock, Daniel
Yin, Shanye
Deng, Stephanie http://orcid.org/0000-0002-0943-1339
Slowik, Kara
Jacobs, Raquel
Huang, Teddy
Li, Shuqiang http://orcid.org/0000-0001-9106-6141
Fell, Geoff http://orcid.org/0000-0001-6436-6691
Redd, Robert http://orcid.org/0000-0002-1329-5288
Lin, Ziao
Knisbacher, Binyamin A. http://orcid.org/0000-0002-4962-9956
Livitz, Dimitri http://orcid.org/0000-0003-2528-1446
Schneider, Christof
Ruthen, Neil http://orcid.org/0000-0002-4409-9503
Elagina, Liudmila
Taylor-Weiner, Amaro http://orcid.org/0000-0002-7249-2425
Persaud, Bria http://orcid.org/0000-0002-1198-4389
Martinez, Aina http://orcid.org/0000-0001-9300-872X
Fernandes, Stacey M.
Purroy, Noelia
Anandappa, Annabelle J.
Ma, Jialin
Hess, Julian http://orcid.org/0000-0003-1387-4009
Rassenti, Laura Z.
Kipps, Thomas J.
Jain, Nitin
Wierda, William http://orcid.org/0000-0002-7357-270X
Cymbalista, Florence
Feugier, Pierre
Kay, Neil E. http://orcid.org/0000-0002-5951-5055
Livak, Kenneth J. http://orcid.org/0000-0001-9105-5856
Danysh, Brian P. http://orcid.org/0000-0001-6839-6337
Stewart, Chip
Neuberg, Donna http://orcid.org/0000-0003-2566-3145
Davids, Matthew S. http://orcid.org/0000-0003-4529-2003
Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
Parida, Laxmi http://orcid.org/0000-0002-7872-5074
Stilgenbauer, Stephan http://orcid.org/0000-0002-6830-9296
Getz, Gad http://orcid.org/0000-0002-0936-0753
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Article History
Received: 23 December 2021
Accepted: 28 October 2022
First Online: 9 January 2023
Competing interests
: I.L. serves as a consultant for PACT Pharma, Inc.; has stock in, is on the board of and serves as a consultant for ennov1 LLC.; and is on the board of and holds equity in Nord Bio, Inc. C.J.W., G.G., B.A.K. and Z.L. are inventors on a patent: ‘Compositions, Panels, and Methods for Characterizing Chronic Lymphocytic Leukemia’ (PCT/US21/45144). C.J.W., G.G., E.M.P., I.L. and R.G. are named as inventors on U.S. provisional patent application serial number 63/244,625, filed on 15 September 2021, and U.S. provisional patent application serial number 63/291,213, filed on 17 December 2021, both of which are entitled ‘Diagnosis and Prognosis of Richter’s Syndrome.’ G.G. is a founder of and consultant for and holds privately held equity in Scorpion Therapeutics; receives funding support from IBM and Pharmacyclics; and is an inventor on patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER and SignatureAnalyzer-GPU. R.G. receives funding support from Abbvie, AstraZeneca, Gilead, Janssen and Roche. M.S.D. served as a consultant for Abbvie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Genentech/Roche, Janssen, Merck, Ono Pharmaceuticals, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, Verastem and Zentalis; receives funding support from Ascentage Pharma, AstraZeneca, Genentech/Roche, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem; and receives funding for travel from Abbvie, BeiGene, BioAscend, Clinical Care Options, Curio Science, Imedex, ION Solutions, Janssen, MDOutlook, PeerView, PRIME Oncology, Research to Practice and TG Therapeutics. J.R.B. has served as a consultant for Abbvie, Acerta/AstraZeneca, BeiGene, Bristol-Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Hutchmed, Janssen, MEI Pharma, MorphoSys AG, Novartis, Pfizer, Pharmacyclics and Rigel; and received research funding from Gilead, Loxo/Lilly, SecuraBio, Sun and TG Therapeutics. C.J.W. receives funding support from Pharmacyclics and holds equity in BioNTech, Inc. N.E.K. serves as an advisor for Abbvie, AstraZeneca, Beigene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology; receives funding support from Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics and Tolero Pharmaceuticals; and participates on the Data Safety Monitoring Committee for Agios Pharm, AstraZeneca, BMS-Celgene, Cytomx Therapeutics, Dren Bio, Janssen, MorphoSys and Rigel. T.J.K. is on the advisory board and receives funding support from Abbvie and Roche and serves on the speakers’ bureau for Abbvie, Janssen and Roche. E.T. serves as an advisor and is on the speakers’ bureau for Abbvie, Janssen and Roche; and receives funding support from Abbvie and Roche. S.S. is on the advisory board and receives funding, travel support and speakers’ fees from AbbVie, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis and Sunesis. N.J. receives research funding from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Aprea Therapeutics, AstraZeneca, BMS, Cellectis, Fate Therapeutics, Genentech, Incyte, Loxo Oncology, Medisix, Mingsight, Novalgen, Pfizer, Pharmacyclics, Precision BioSciences, Servier and Takeda; and serves on the advisory board/receives honoraria from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Beigene, BMS, Cellectis, Genentech, Janssen, MEI Pharma, Pharmacyclics, Precision BioSciences, Servier and TG Therapeutics. W.G.W. reports funding from Abbvie, AstraZeneca/Acerta Pharma, Cyclacel, Genentech, Gilead Sciences, GSK/Novartis, Janssen, Juno Therapeutics, KITE Pharma, Loxo Oncology, Inc., Miragen, Oncternal Therapeutics, Inc., Pharmacyclics LLC, Sunesis and Xencor. S.A.P. has received research funding to the institution from AbbVie, Ascentage Pharma, AstraZeneca, Janssen, Merck, Pharmacyclics and TG Therapeutics for clinical studies in which S.A.P. is a principal investigator. S.A.P has received honoraria for participation in consulting activities/advisory board meetings for AbbVie, Adaptive Biotechnologies, Amgen, AstraZeneca, Genentech, GlaxoSmithKline, Merck and Pharmacyclics (no personal compensation). K.J.L. holds equity in Standard BioTools, Inc. D.N. has stock ownership in Madrigal Pharmaceuticals. C.S. serves on a speakers’ bureau for AbbVie and AstraZeneca. D.L. holds stock in and consults for ennov1. N.P is currently an employee at Bristol Meyers Squibb. All remaining authors declare no competing interests.